Fate CEO Exits for New Co

Fate Therapeutics, the San Diego-based developer of stem cell therapies, said today that CEO Paul Grayson is leaving Fate to form a new company. The new company wasn’t named in today’s release, and Fate didn’t say who will replace Grayson, although Fate’s website still lists John Mendlein as executive chairman. Grayson, who was previously a managing director with Sanderling Ventures, led Fate for three years.

Trending on Xconomy